Quantcast
Last updated on April 23, 2014 at 13:36 EDT

Latest N30 Pharmaceuticals Inc. Stories

2014-03-12 08:29:44

BOULDER, Colo., March 12, 2014 /PRNewswire/ -- N30 Pharmaceuticals, Inc. ("N30 Pharma") announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF). In preclinical studies, N91115 has been shown to rescue or "correct" F508del-CFTR, the most commonly occurring mutation in CF. It is the first oral GSNOR inhibitor to enter clinical...

2013-10-15 08:29:53

BOULDER, Colo., Oct. 15, 2013 /PRNewswire/ -- N30 Pharmaceuticals, Inc. today announced presentations regarding its novel portfolio of compounds for the potential treatment of cystic fibrosis at the 2013 North American Cystic Fibrosis Conference, which will be held October 17-19, 2013 in Salt Lake City, Utah. The presentations include preclinical data on its first-in-class inhibitors of S-nitrosoglutathione reductase (GSNORi) and its novel correctors of CFTR, the dysfunctional protein...

2013-03-13 08:30:43

BOULDER, Colo., March 13, 2013 /PRNewswire/ -- N30 Pharmaceuticals, Inc. ("N30 Pharma") a leader in the development of therapeutics that target S-nitrosoglutathione reductase (GSNOR), announced today that it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis (CF). The study is a multicenter, double-blind, randomized, placebo-controlled evaluation of ascending doses of N6022 in patients who have two copies of the F508del-CFTR mutation,...

2012-10-08 07:23:37

BOULDER, Colo., Oct. 8, 2012 /PRNewswire/ -- N30 Pharmaceuticals, Inc. today announced the addition of Dr. Sherif Gabriel to its senior leadership team. Prior to joining N30 Pharma, Dr. Gabriel was on the faculty of the University of North Carolina Cystic Fibrosis Center, Director of the Cystic Fibrosis Correction Core of the Center, and Associate Professor in the Department of Pediatrics, Division of Pulmonology. Dr. Gabriel's career has revolved around the molecular regulation of ion and...